HUMACYTE INC (HUMA) Stock Price, Quote, News and Overview
NASDAQ:HUMA - Nasdaq - US44486Q1031 - Common Stock - Currency: USD
HUMA Quote, Performance and Key Statistics
3.06
-0.34 (-10%)
The current stock price of HUMA is 3.06 USD. In the past month the price decreased by -33.19%. In the past year, price decreased by -9.2%.
HUMA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.9 | 373.71B | ||
| AMGN | AMGEN INC | 15.68 | 166.89B | ||
| GILD | GILEAD SCIENCES INC | 25.16 | 144.52B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1666.59 | 124.16B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.01 | 74.87B | ||
| ARGX | ARGENX SE - ADR | 241.32 | 37.83B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.41B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.75B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.20B | ||
| BIIB | BIOGEN INC | 8.6 | 20.65B | ||
| NTRA | NATERA INC | N/A | 18.89B | ||
| GMAB | GENMAB A/S -SP ADR | 24.69 | 14.59B |
Related stock screener links
About HUMA
Company Profile
Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company is headquartered in Durham, North Carolina and currently employs 183 full-time employees. The company went IPO on 2020-09-22. The firm is engaged in developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction, and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The firm has developed a novel paradigm for manufacturing human tissues that are intended to mimic key aspects of human physiology. The company is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes. The Company’s scientific technology platform uses primary human aortic vascular cells from a working cell stock, isolated from donor tissues and cryopreserved.
Company Info
HUMACYTE INC
2525 East North Carolina Highway 54
Durham NORTH CAROLINA US
CEO: Rajiv Shukla
Employees: 184
Company Website: https://humacyte.com/
Investor Relations: https://humacyte.gcs-web.com/
Phone: 19193139633
HUMACYTE INC / HUMA FAQ
What is the stock price of HUMACYTE INC today?
The current stock price of HUMA is 3.06 USD. The price decreased by -10% in the last trading session.
What is the ticker symbol for HUMACYTE INC stock?
The exchange symbol of HUMACYTE INC is HUMA and it is listed on the Nasdaq exchange.
On which exchange is HUMA stock listed?
HUMA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for HUMACYTE INC stock?
13 analysts have analysed HUMA and the average price target is 13.41 USD. This implies a price increase of 338.1% is expected in the next year compared to the current price of 3.06. Check the HUMACYTE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is HUMACYTE INC worth?
HUMACYTE INC (HUMA) has a market capitalization of 375.31M USD. This makes HUMA a Small Cap stock.
How many employees does HUMACYTE INC have?
HUMACYTE INC (HUMA) currently has 184 employees.
What are the support and resistance levels for HUMACYTE INC (HUMA) stock?
HUMACYTE INC (HUMA) has a resistance level at 3.44. Check the full technical report for a detailed analysis of HUMA support and resistance levels.
Is HUMACYTE INC (HUMA) expected to grow?
The Revenue of HUMACYTE INC (HUMA) is expected to grow by 275.03% in the next year. Check the estimates tab for more information on the HUMA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy HUMACYTE INC (HUMA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HUMA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HUMA, evaluating the profitability, health, valuation and growth aspects
- HUMACYTE INC (HUMA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- HUMACYTE INC (HUMA) Sales and EPS estimates to see what analysts future expectations are.
- HUMACYTE INC (HUMA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- HUMACYTE INC (HUMA) Insider and Institutional Ownership to learn about the owners and their transactions.
- HUMACYTE INC (HUMA) Stock Chart to make your own analysis
- HUMACYTE INC (HUMA) Latest news and press-releases to stay up to date.
Does HUMACYTE INC (HUMA) stock pay dividends?
HUMA does not pay a dividend.
When does HUMACYTE INC (HUMA) report earnings?
HUMACYTE INC (HUMA) will report earnings on 2025-03-21, after the market close.
What is the Price/Earnings (PE) ratio of HUMACYTE INC (HUMA)?
HUMACYTE INC (HUMA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.34).
What is the Short Interest ratio of HUMACYTE INC (HUMA) stock?
The outstanding short interest for HUMACYTE INC (HUMA) is 26.81% of its float. Check the ownership tab for more information on the HUMA short interest.
HUMA Technical Analysis
HUMA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to HUMA. HUMA has a bad profitability rating. Also its financial health evaluation is rather negative.
HUMA Financial Highlights
Over the last trailing twelve months HUMA reported a non-GAAP Earnings per Share(EPS) of -1.34. The EPS decreased by -54.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -133.2% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
HUMA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to HUMA. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -24.33% and a revenue growth 275.03% for HUMA